Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Alexion Pharm Inc (ALXN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 27,490,560
  • Shares Outstanding, K 224,250
  • Annual Sales, $ 2,604 M
  • Annual Income, $ 144 M
  • 36-Month Beta 1.41
  • Price/Sales 10.51
  • Price/Book 3.22

Price Performance

See More
Period Period Low Period High Performance
1-Month
111.67 +10.11%
on 11/11/16
145.41 -15.44%
on 11/04/16
-4.78 (-3.74%)
since 11/02/16
3-Month
111.67 +10.11%
on 11/11/16
145.41 -15.44%
on 11/04/16
-0.71 (-0.57%)
since 09/02/16
52-Week
110.56 +11.22%
on 06/24/16
193.45 -36.44%
on 12/31/15
-53.62 (-30.37%)
since 12/02/15

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alexion Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ALXN

Pomerantz LLP announces that a class action lawsuit has been filed against Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (NASDAQ:ALXN) and certain of its officers. The class action, filed...

SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 1, 2016 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company")...

Lifshitz & Miller Law Firm Announces Investigation of Alexion Pharmaceuticals, Inc., Blue Nile, Inc., Hill International, Inc., InfuSystem Holdings Inc., Rent-A-Center, Inc., Treehouse Foods, Inc. and Viking Investments Group, Inc.

Alexion Pharmaceuticals, Inc. (ALXN)

SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / November 30, 2016 / Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (Nasdaq: ALXN)....

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alexion Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 -- ALXN

NEW YORK, NY--(Marketwired - November 30, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alexion Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 -- ALXN

NEW YORK, NY--(Marketwired - November 30, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:

Lawsuit for Investors in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares announced by Shareholders Foundation

The Shareholders Foundation, Inc. announces that a lawsuit was filed in New York on behalf of certain purchasers of shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) over alleged Securities Laws Violations...

SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Alexion Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline - ALXN

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline: January 17, 2017

NEW YORK, NY / ACCESSWIRE / November 24, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Alexion Pharmaceuticals, Inc. ("Alexion" or the...

Biotech Stock Roundup: Acorda Stops Ampyra PSWD Development, CRL for Spectrum's Qapzola

Focus is back on pipeline and regulatory updates with the end of the third quarter earnings season and elections.

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Weakest.

See More

Business Summary

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system...

See More

Support & Resistance

2nd Resistance Point 124.69
1st Resistance Point 123.83
Last Price 122.96
1st Support Level 121.72
2nd Support Level 120.47

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.